
	Three Months Ended June 30,
	2026		2025
Finance Lease Costs
Research and development	$	607	$	607
Other expenses	506		521
Operating Lease Costs
Research and development	215		223
Selling, general and administrative	74		65
Total lease cost	$	1,402	$	1,416

The following table summarizes the maturity of the Company's lease liabilities on an undiscounted cash flow basis by fiscal year and a reconciliation to the operating and finance lease liabilities recognized on its balance sheet as of June 30, 2026:


	June 30, 2026
	Operating leases		Finance lease		Total
2027 (remaining nine months)	$	861	$	2,175	$	3,036
2028	1,107		2,969		4,076
2029	1,021		3,058		4,079
2030	588		3,096		3,684
2031	370		3,096		3,466
Thereafter	—		25,802		25,802
Total lease payments	3,947		40,196		44,143
Less: interest	675		15,607		16,282
Total lease liabilities	$	3,272	$	24,589	$	27,861


	Three Months Ended June 30,
	2026				2025
Other information
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	302			$	299
Operating cash flows from finance leases	$	506			$	521
Financing cash flows from finance leases	$	203			$	166
Weighted-average remaining lease term - operating leases	3.6			years	4.5			years
Weighted-average remaining lease term - finance leases	13.1			years	14.1			years
Weighted-average discount rate - operating leases	10.4		%		10.5		%
Weighted-average discount rate - finance leases	8.3		%		8.3		%

The Company has entered into an agreement with a contract manufacturing organization to provide clinical trial products. As of June 30, 2026 and March 31, 2026, the Company had committed to minimum payments under these arrangements totaling $0.8 million and $0.8 million, respectively.

In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its executive management team and its board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and therefore it has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of June 30, 2026 or March 31, 2026.

From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. The Company records a liability for such matters when it is probable that future losses will be incurred and that such losses can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount.

On July 24, 2025, a class action complaint alleging violations of the federal securities laws was filed against the Company and its directors and certain officers in the United States District Court for the District of Massachusetts, or the District of Massachusetts. The complaint, captioned Jboor v. Replimune Group, Inc. et al., Case No. 1:25-cv-12085-JEK, was filed shortly after the Company announced it received a complete response letter from the FDA for its RP1 BLA for the treatment of advanced melanoma on July 22, 2025 and the subsequent decline in the trading price of the Company's common stock. The Court has appointed a lead plaintiff, or the Lead Plaintiff. On January 13, 2026, Lead Plaintiff filed an amended complaint. Following the second CRL issued by the FDA on April 10, 2026 for the Company's RP1 BLA for the treatment of advanced melanoma, the Lead Plaintiff filed a second amended complaint in the class action that addresses the second CRL. The Company’s and the other defendants’ response is now due on August 17, 2026. The Company and the other defendants deny any wrongdoing and continue to vigorously defend this action.

Following the class action complaint, three shareholders filed separate derivative actions on behalf of the Company in the District of Massachusetts captioned Chea v. Patel et al., Case No. 1:25-cv-12316-JEK, Wright v. Patel et al., Case No. 1:25-cv-12401-WGY, and Vochten v. Patel et al., Case No. 1:25-cv-12484-JEK. The plaintiffs allege substantially similar facts as the class action complaint and assert that the Company’s directors and officers breached their fiduciary duties. The parties have consolidated the derivative actions and agreed to a stay pending further developments in the class action.

On September 10, 2025, the Company received a letter from a shareholder demanding that the Company's board of directors take action to address alleged wrongdoing by certain directors and officers. The demand letter alleged substantially similar facts as the class action and derivative action complaints. The board of directors determined to defer action on the demand pending further developments in the class action.

On September 29, 2025, the SEC informed the Company that it was conducting an investigation and requested that the Company produce certain documents and communications connected with the RP1 BLA. The investigation is reviewing essentially the same subject matter raised in the litigation following the CRL. On June 24, 2026, the SEC informed the Company that it has concluded its investigation of the Company and that it is not recommending an enforcement action be taken against the Company.

On August 6, 2026, a class action complaint alleging violations of the federal securities laws was filed against the Company and its directors and certain officers in the District of Massachusetts. The complaint, captioned Toor v. Replimune Group, Inc. et al., Case No. 1:26-cv-13612, alleges essentially the same facts and circumstances as the Lead Plaintiff's case. The Company and the other defendants deny any wrongdoing and continue to vigorously defend this action.

As the matters noted above are preliminary, the Company is unable to determine whether any loss will ultimately occur and cannot reasonably estimate the range of expected exposure. Therefore, the Company has not recorded any liability in the condensed consolidated financial statements as of and for the three months ended June 30, 2026.